Product Name :
Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
EN
programmed cell death protein 1, PD1, CD279, cluster of differentiation 279
Source:
The anti-human PD-1 monoclonal antibody camrelizumab biosimilar was produced in the camrelizumab biosimilar CHO stable cell line.
Molecular Weight:
Activity :
Purity:
>95% by SDS-PAGE under reducing conditions and HPLC.
Endotoxin :
< 1 EU per 1 mg of the protein by the LAL method.
Formulation:
Reconstitution :
Shipping:
The research grade camrelizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
/strong>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Form of Antibody :
0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Clone:
Isotype:
Human IgG4-k kappa.
Background:
Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018. Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins: Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars: Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies: In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1) In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1) In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
Additional Information:
| Camrelizumab Biosimilar, PD-1 Monoclonal Antibody Recombinant Humanized IgG4-k Monoclonal Antibody. |Isotype: Human IgG4-k kap|The anti-human PD-1 monoclonal antibody camrelizumab biosimilar was produced in the camrelizumab biosimilar CHO stable cell line. |Specificity/Sensitivity: The in vivo grade camrelizumab biosimilar specifically binds to the programmed cell death protein 1 (PD1), antagonizing its interaction with its known ligands PD-L1 and PD-L2. |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade camrelizumab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for he|Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody S|Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies: In vivo grade recombinant anti-mouse PD1 monoclonal antibodies (Clone 29F.1A12.1) In vivo grade recombinant anti-mouse PD-1 monoclonal antibodies (Clone RMP1-14.1) In vivo grade recombinant anti-mouse PD-L1 monoclonal antibodies (Clone 10F.9G2.1)
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Bcl2 Antibody
Integrin alpha 5 Antibody
Glucosidase 2 subunit beta Antibody: Glucosidase 2 subunit beta Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 59 kDa., targeting to Glucosidase 2 subunit beta. It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human.
